| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C20H21N3O3S |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
MPH-220 is a selective, orally active inhibitor of skeletal muscle myosin-2 that enables muscle relaxation. As an anti-spastic agent, it can be used to study spasticity and muscle stiffness[1]. It is supplied as an orange to red solid (C20H21N3O3S, MW 383.46) at 99.25% purity.
Physical & Chemical Properties
| CAS Number | 2649776-79-2 |
|---|---|
| Molecular Formula | C20H21N3O3S |
| Molecular Weight | 383.46 g/mol |
| Purity | 99.25% |
| Appearance | Solid |
| Color | Orange to red |
| SMILES | O[C@@]12C(N(C3=CC=C(N4CCOCC4)C=C3)CC2)=NC5=C(C=C(S5)C)C1=O |
| Signaling Pathway | Cytoskeleton |
| Solubility | In Vitro: DMSO: 100 mg/mL (260.78 mM; Requires sonication and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (260.78 mM) | requires sonication and warming; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
Data provided by the manufacturer.
In Vitro
In human muscle myosin samples, MPH-220 (0-50 μM) inhibits actin-activated ATPase activity[1].
In Vivo
In anesthetized rats, MPH-220 (25-30 mg/kg, i.p. or oral gavage) lowers skeletal muscle force with no cardiovascular effects[1]. In rats with brain injury, MPH-220 (15 mg/kg, oral administration) improves gait function[1].
| Animal Model | Anesthetized rats[1] |
|---|---|
| Dosage | 25-30 mg/kg |
| Administration | Intraperitoneal injection (i.p.) or oral gavage |
| Result | Reduced skeletal muscle force. Observed MPH-220 distribution in rat tissues in a time-dependent manner and a dose-dependent, few-fold accumulation in skeletal muscle. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
bioRxiv. 2025 Oct 17.
